Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
March 05, 2025 16:01 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Announces New Employment Inducement Grants
February 20, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 18, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
December 17, 2024 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas
November 25, 2024 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference